News
News
DynamX Bioadaptor Restores Rotational Motion and Vessel Stress Reduction in New Study
A study in the latest issue of Cardiovascular Revascularization Medicines hows that the DynamX™ Coronary Bioadaptor System, when uncaged, enabled rotational motion similar to natural vessels.
Elixir Medical Strengthens its Commercial Capabilities with the Addition of Ahram as Executive Vice President, International
Ahram possesses more than 25 years of leadership experience and successes in building new markets and accelerating commercialization for novel medical devices across Asia, Europe, and the Middle East.
Elixir Medical Expands Bioadaptor Randomized Controlled Trial of DynamX Coronary Bioadaptor System
MILPITAS, Calif. – April 22, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding
Elixir Medical Announces Commencement Of Infinity-Swedeheart Randomized Controlled Trial of DynamX Coronary Bioadaptor System
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif.
Elixir Medical Announces Outstanding 24-Month Data for DynamX Coronary Bioadaptor System, Demonstrating Strong Safety With No Target Lesion Revascularization, Myocardial Infarction Or Thrombosis Through 24 Months
Successful DynamX Bioadaptor Live Case Presented at Singapore Live MILPITAS, Calif. – January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the
Elixir Medical Announces First Patient Treated in Bioadaptor Randomized Controlled Trial of DynamX Coronary Bioadaptor System
International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents MILPITAS, Calif. – January
Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No Thrombosis and Positive Adaptive Remodeling of the Artery
PARIS – June 25, 2020 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX™ Coronary Bioadaptor System, the first
Elixir Medical Corporation Announces Outstanding 5-Year Clinical Data for CE Mark-Approved DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
Excellent Six-Month Safety and Efficacy Results for Next-Generation Thin-strut DESolve® Cx Novolimus Eluting Bioresorbable Coronary Scaffold System also presented Milpitas, CA – May 17, 2017 — Elixir Medical Corporation,
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments That Uncage the Stented Artery
Elixir Reveals New Category of ‘Bioadaptive Drug Eluting Stents’ (BA- DES), Sharing DynamX Technology, Preclinical Data, and Clinical Program at 29th Transcatheter Cardiovascular Therapeutics Conference
PMN 1714 Rev A